Attomarker
Private Company
Total funding raised: $1.7M
Overview
Attomarker is a private, commercial-stage diagnostics company founded in 2016 as a spin-out from the University of Exeter. It has developed a proprietary multiplex diagnostic platform that uses gold nanoparticle nanotechnology and microfluidics to provide quantitative, multi-biomarker results in approximately seven minutes. The company is currently generating early revenue from its first authorized test for Long COVID immune profiling and is actively fundraising to scale its platform and expand its test pipeline into areas like Lyme disease, fertility, and liver health.
Technology Platform
Integrated platform using gold nanoparticle nanotechnology, microfluidics, and data analytics for rapid, quantitative, multiplexed biomarker testing from a blood sample.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Attomarker competes in the multiplex and point-of-care diagnostics space against large established players (e.g., Roche, Abbott, Siemens) and other innovative startups. Its differentiation lies in the combination of rapid results (7 minutes), true quantitative multiplexing, and a focus on complex immune profiling, a niche less served by traditional lateral flow or single-analyte tests.